To enhance the efficacy of neoadjuvant ICB, and based on the additive effect observed in the metastatic setting [46], neoadjuvant ICB plus chemotherapy and perioperative ICB strategies have also been explored in resectable early-stage EGFR/ALK-wildtype NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.